Location History:
- Concord, MA (US) (2018 - 2021)
- Bridgewater, NJ (US) (2021)
Company Filing History:
3 out of 787 
1 out of 16 Years Active: 2018-2021
Title: Innovations by Gina Lacorcia
Introduction
Gina Lacorcia is a prominent inventor based in Concord, MA (US). She has made significant contributions to the field of immunology, particularly through her work on monoclonal antibodies. With a total of three patents to her name, her innovations are paving the way for advancements in immunosuppressive therapies.
Latest Patents
Gina Lacorcia's latest patents include the development of an anti-αβTCR antibody. This invention relates to humanized monoclonal antibodies that comprise the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties. Another notable patent focuses on methods for enhancing immunosuppressive therapy through the multiple administration of αβTCR-binding polypeptides. This disclosure details improved methods for using a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR). Additionally, she has developed novel methods using humanized monoclonal antibodies and/or fragments to reduce αβ T cells in subjects relative to γδ cells.
Career Highlights
Throughout her career, Gina has worked with notable organizations such as Genzyme Corporation and Eberhard Karls Universität Tübingen. Her experience in these institutions has contributed to her expertise in the field of immunology and antibody development.
Collaborations
Gina has collaborated with esteemed colleagues, including Daniel Snell and Andreas Menrad. These partnerships have further enriched her research and innovations in the field.
Conclusion
Gina Lacorcia's work exemplifies the impact of innovative thinking in the realm of immunology. Her patents and collaborations highlight her commitment to advancing medical science through her inventions.